

Johnson & Johnson to Acquire \$2 Billion Drug Developer “Ambrx Biopharma” to Treat Turbo Cancers with Same Tech as Pfizer’s \$43 Billion Seagen Acquisition

Both set their sights on 2025 Cancer TSUNAMI

By [Dr. William Makis](#)

Theme: [Science and Medicine](#)

Global Research, January 17, 2024

[COVID Intel](#)

All Global Research articles can be read in 51 languages by activating the Translate Website button below the author’s name (only available in desktop version).

To receive Global Research’s Daily Newsletter (selected articles), [click here](#).

Click the share button above to email/forward this article to your friends and colleagues. Follow us on [Instagram](#) and [Twitter](#) and subscribe to our [Telegram Channel](#). Feel free to repost and share widely Global Research articles.

[New Year Donation Drive: Global Research Is Committed to the “Unspoken Truth”](#)

[Jan. 8, 2024 \(CNBC\)](#) – J&J to acquire cancer drug developer Ambrx Biopharma for \$2 billion

- Johnson & Johnson said it will acquire Ambrx Biopharma for \$2 billion, picking up a drugmaker specializing in one of the hottest areas of cancer treatment.
- The deal makes J&J the latest drugmaker to bet on antibody-drug conjugates, or ADCs (same tech as Pfizer’s latest \$43 billion Seagen acquisition)
- The acquisition also comes as J&J scrambles to fill a revenue hole that’s approaching in 2025 (!)
- [Johnson & Johnson](#) on Monday said it will [pay \\$2 billion in cash](#) to acquire [Ambrx Biopharma](#)
- “Ambrx’s pipeline and ADC platform present exciting future opportunities to deliver enhanced, precision biologics as we look to transform the treatment of cancer and improve patients’ lives”
- Under the terms of the deal, J&J will pay \$28 a share for Ambrx, or about DOUBLE the firm’s Friday closing price of \$13.63. J&J expects to close the deal in the first half of 2024.

[Jan. 9, 2024 \(Health & Pharma\)](#) – J&J’s \$2 Billion Strategic Acquisition of Ambrx Biopharma: Leading in ADC Oncology

- Johnson & Johnson announced the acquisition of Ambrx Biopharma for \$2 billion,

aiming to boost its oncology pipeline with Ambrx's innovative antibody drug conjugates

- This strategic move focuses on targeted therapies like ARX517 for prostate cancer
- ADCs, a class of therapeutics that combines the specificity of monoclonal antibodies with the potency of cytotoxic drugs, aiming to target and destroy cancer cells more effectively
- The jewel in Ambrx's crown is ARX517, their proprietary ADC targeting Prostate-Specific Membrane Antigen (PSMA) for treating metastatic castration-resistant prostate cancer (mCRPC)
- In addition to ARX517, Ambrx's portfolio includes other promising ADCs like ARX788, targeted at HER2+ metastatic breast cancer
- ARX305, its proprietary ADC targeting CD-70 for renal cell carcinoma.

Jan. 8, 2024 (Businesswire) – Johnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates to Transform the Treatment of Cancer

- Johnson & Johnson (NYSE: JNJ) announced today it has entered into a definitive agreement to acquire Ambrx Biopharma, Inc., or Ambrx, a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs), in an all-cash merger transaction for a total equity value of \$2.0 billion
- results seen to date with ARX517 in mCRPC (prostate cancer) are promising and represent a potential first- and best-in-class targeted therapy for the treatment of this aggressive disease.
- Ambrx's proprietary ADC technology incorporates the advantages of highly specific targeting monoclonal antibodies securely linked to a potent chemotherapeutic payload to achieve targeted and efficient elimination of cancer cells without the prevalent side-effects typically associated with chemotherapy
- Following completion of the transaction, Ambrx's common stock will no longer be listed for trading on the NASDAQ Global Select Market.

Turbo Cancers

This is my original prediction about COVID-19 mRNA Vaccine Induced Turbo Cancers, which may change slightly over time as more data comes in.

Top 5 Turbo Cancers by # of people who will be affected long term:

1. Lymphoma (various types)
2. Brain Cancers (mostly glioblastoma)
3. Breast Cancer (mostly triple negative)
4. Colon Cancer
5. Lung Cancer

Top 10 Turbo Cancers by # of people affected (no particular order):

- leukemias
- melanomas

- sarcomas
- testicular/ovarian
- kidney

[Dec. 14, 2023](#) – Pfizer’s \$43 billion acquisition of Seagen

- Pfizer has positioned itself to be able to treat 7 of the top 10 Turbo Cancers as I have identified at this early stage.
- Seagen added ADC cancer drugs (or drugs in pipeline) to Pfizer to treat: lymphoma, breast, colorectal, lung, as well as cancers not in my top 10: cervical, urothelial bladder and multiple myeloma.

Johnson & Johnson adds:

- This \$2 billion acquisition gives J&J the ability to use the same ADC technology as Pfizer’s \$43 billion Seagen, to treat 2 of the top 10 turbo cancers: breast cancer and kidney cancer.
- I have not seen a major spike in prostate cancer yet, but they may know something I don’t.

My Take...

Many pharmaceutical companies are rushing to position themselves to profit from treating a tsunami of cancers that they are all expecting to hit starting in 2025.

- [Dec. 14, 2023](#) – Pfizer closed a \$43 billion acquisition to treat several turbo cancers on Dec.14, 2023 and expects to “fill a gap” for the period 2025-2030.
- [Dec. 14, 2023](#) – Moderna targets new mRNA Cancer vaccine to treat melanoma to be available by 2025
- [Jan. 8, 2024](#) – Johnson & Johnson to acquire \$2 billion cancer drug company that uses same tech as Pfizer, to “fill a revenue gap in 2025”
- [Jan. 10, 2024](#) – BioNTech expects to return to revenue growth in 2025, when its COVID vaccine business would bottom out, and it would invest to “scale up its oncology business thereafter”
- [Oct.12, 2023](#) – Dxcover targets 2025 launch for blood test that uses light to detect brain cancer
- [Sep.2023](#) – Harbinger Health raises \$140M to study blood-based cancer screening test – ahead of a planned launch in 2025.
- [Jun.1, 2023](#) – Multi-cancer blood test shows real promise in NHS study – NHS in England plans to extend the rollout to a further one million people in 2024 and 2025

Cancer Centers to Open by 2025

- [Aug. 2023](#) – Cape Breton (NS, Canada) Cancer centre to open in 2025
- [Jul. 2023](#) – \$120M Cancer center (Tennessee Oncology) set for 2025 finish
- [Jun. 2023](#) – \$200M Cancer center set to open in NJ in 2025
- [Mar. 2023](#) – Orange County’s only cancer specialty hospital will open in 2025
- [May 2023](#) – Kearney, Nebraska to welcome new cancer center in 2025
- [Jan. 2023](#) – OU Health to open cancer center in 2025

- [Dec. 2022](#) – \$2 billion Alberta, Canada cancer centre to open in 2024
- [Aug. 2022](#) – Baltimore, MD – Sinai Hospital to build cancer center by 2025
- [Jul. 2022](#) – Wales – New Velindre cancer centre to open in 2025
- [Dec. 2023](#) – 123 cancer centers opening, expanding, affiliating in 2023

It seems the population is the last to know, but everyone from the largest pharmaceutical companies, to politicians, and healthcare providers are all betting on a tsunami of cancers starting in 2025.


Johnson & Johnson is just the latest company to secure a piece of the pie, now that they've paid a \$700 million settlement for the Talc baby powder scandal.

And they overpaid the latest acquisition by more than 100% of the current stock price.

*

Note to readers: Please click the share button above. Follow us on Instagram and Twitter and subscribe to our Telegram Channel. Feel free to repost and share widely Global Research articles.

Dr. William Makis is a Canadian physician with expertise in Radiology, Oncology and Immunology. Governor General's Medal, University of Toronto Scholar. Author of 100+ peer-reviewed medical publications.



The Worldwide Corona Crisis, Global Coup d'Etat Against Humanity

by Michel Chossudovsky

Michel Chossudovsky reviews in detail how this insidious project “destroys people’s lives”. He provides a comprehensive analysis of everything you need to know about the “pandemic” — from the medical dimensions to the economic and social repercussions, political underpinnings, and mental and psychological impacts.

“My objective as an author is to inform people worldwide and refute the official narrative which has been used as a justification to destabilize the economic and social fabric of entire countries, followed by the imposition of the “deadly” COVID-19 “vaccine”. This crisis affects humanity in its entirety: almost 8 billion people. We stand in solidarity with our fellow human beings and our children worldwide. Truth is a powerful instrument.”

Reviews

This is an in-depth resource of great interest if it is the wider perspective you are motivated to understand a little better, the author is very knowledgeable about geopolitics and this comes out in the way Covid is contextualized. —Dr. Mike Yeadon

In this war against humanity in which we find ourselves, in this singular, irregular and massive assault against liberty and the goodness of people, Chossudovsky's book is a rock upon which to sustain our fight. —Dr. Emanuel Garcia

In fifteen concise science-based chapters, Michel traces the false covid pandemic, explaining how a PCR test, producing up to 97% proven false positives, combined with a relentless 24/7 fear campaign, was able to create a worldwide panic-laden "plandemic"; that this plandemic would never have been possible without the infamous DNA-modifying Polymerase Chain Reaction test – which to this day is being pushed on a majority of innocent people who have no clue. His conclusions are evidenced by renown scientists. —Peter Koenig

Professor Chossudovsky exposes the truth that "there is no causal relationship between the virus and economic variables." In other words, it was not COVID-19 but, rather, the deliberate implementation of the illogical, scientifically baseless lockdowns that caused the shutdown of the global economy. —David Skripac

A reading of Chossudovsky's book provides a comprehensive lesson in how there is a global coup d'état under way called "The Great Reset" that if not resisted and defeated by freedom loving people everywhere will result in a dystopian future not yet imagined. Pass on this free gift from Professor Chossudovsky before it's too late. You will not find so much valuable information and analysis in one place. —Edward Curtin

ISBN: 978-0-9879389-3-0, Year: 2022, PDF Ebook, Pages: 164, 15 Chapters

Price: ~~\$11.50~~ FREE COPY! [Click here \(docsend\) and download.](#)

We encourage you to support the eBook project by making a donation through Global Research's [DonorBox "Worldwide Corona Crisis" Campaign Page](#).

The original source of this article is [COVID Intel](#)
Copyright © [Dr. William Makis](#), [COVID Intel](#), 2024

[Comment on Global Research Articles on our Facebook page](#)

[Become a Member of Global Research](#)

Articles by: [Dr. William Makis](#)

not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca